A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Inclusion criteria * Age of 28 days \< 18 years. * Dry weight ≥ 7 kg during screening. * Diagnosed with CKD and SHPT undergoing hemodialysis at the time of screening. * Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values ≥ 300 pg/mL (32 pmol/L) during screening, on separate days and within 2 weeks of enrolment. * Serum corrected calcium (cCa) value ≥ 9.0 mg/dL (2.25 mmol/L) for participants ≥ 2 years of age and older and serum cCa value ≥ 9.6 mg/dL (2.4 mmol/L) for participants 28 days to \< 2 years of age obtained from the central laboratory during screening. * Dialysate Ca level ≥ 2.5 mEq/L during screening for at least 4 weeks prior to screening and throughout the duration of the trial. * No more than a maximum prescribed dose change of 50% for active vitamin D sterols/phosphate binders/Ca supplements within the 2 weeks prior to screening assessments and remain stable. * SHPT not due to vitamin D deficiency, per investigator assessment. Exclusion Criteria Disease Related * History of congenital long QT syndrome, second or third degree heart block, ventricular tachyarrhythmia's or other conditions associated with prolonged QT interval. * Anticipated or scheduled parathyroidectomy during the trial period. * Anticipated or scheduled kidney transplant during the trial period. * Participant has received a parathyroidectomy within 6 months prior to randomization. Other Medical Conditions • History of other malignancy, except non-melanoma skin…